Back to search

National and Kapodistrian University of Athens

Μελέτη των μηχανισμών δράσης της κυκλοσπορίνης σε καλλιέργειες περιφερικών λεμφοκυττάρων και στο περιφερικό αίμα ασθενών με ψωρίαση

Abstract

dc:description

Cyclosporine A (CsA) has been used therapeutically as immunosupressive agent in several autoimmune diseases. The initial purpose of this study was to investigate the in vitro effect of cyclosporine in peripheral lymphocyte cultures, with an emphasis on the proliferation of peripheral lymphocytes and isolated Β lymphocytes as well as on the release and production of soluble molecules such as sCD23, slL-2R and immunoglobulin IgM. Additionally, the in vivo effect of CsA was investigated in corresponding immunological parametes of psoriasic patients and for comparative reasons in a group of healthy subjects. The conditions of release and serum levels of slL-2R were assessed since elevated slL-2R levels are indicative for T-cell activation, lnterleukin-2 is produced by activated Τ lymphocytes and exerts its biological activity by binding to a high affinity receptor complex on the surface of Τ and Β lymphocytes. The soluble form of the receptor has been shown to be released by human activated Τ and Β lymphocytes in vitro and it has been suggested that slL-2R binds circulating IL-2. The conditions of release of the soluble form of the CD23 antigen (sCD23), were also investigated since this molecule has been shown to induce Β cell activation and differentiation. slCAM-1 is the soluble form of ICAM-1, which is known to be the ligand of LFA-1 (lymphocyte function associate antigen). Since high levels of slCAM-1 have been reported in patients with skin diseases, slCAM-1 was thought to be a proper marker in the present study and its levels were measured in the serum of psoriatic patients. The same immunological factors were investigated in the serum of psoriasic patients that undergo CsA treatment, as well as the levels of IL-2 and IL-12, the levels of immunoglobulins, complement factors and neopterin (T-cell and macrophage activation marker). Moreover, the subpopulations of Β and Τ lymphocytes (activated or not) and natural killer cells (NK), were identified in the basis of their cellsurfase markers. The main purpose of these experiments was the comparison of the activation markers in samples taken before the administration of CsA, and 15 days, 3, 6 and 12 months after the initiation of CsA therapy. The same activation markers were measured in samples taken from healthy subjects considered as a set, as far as concerns the age and the sex of the patients. The most important findings of this study were the following: 1. The in vitro study demonstrated that cyclosporine, can under the experimental conditions used, either suppress signals for proliferation and activation of lymphocytes or upregulate certain lymphocyte functions...

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2008

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Barkis, John
  • Μπάρκης, Ιωάννης

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/23552

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Barkis, John; Μπάρκης, Ιωάννης. Μελέτη των μηχανισμών δράσης της κυκλοσπορίνης σε καλλιέργειες περιφερικών λεμφοκυττάρων και στο περιφερικό αίμα ασθενών με ψωρίαση. National and Kapodistrian University of Athens, 2008. http://hdl.handle.net/10442/hedi/23552